Prospective evaluation of the effect of deferasirox on hematologic response in transfusion-dependent patients with low-risk MDS and iron overload.
Fiche publication
Date publication
mai 2018
Journal
European journal of haematology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr AME Shanti
Tous les auteurs :
Rose C, Lenoir C, Gyan E, Hacini M, Amé S, Corront B, Beyne-Rauzy O, Adiko D, Loppinet E, Ali-Ammar N, Laribi K, Wattel E, Dreyfus F, Roué CS, Cheze S
Lien Pubmed
Résumé
To assess the reduction of transfusions rate in transfusion-dependent patients with low-risk myelodysplastic syndrome (MDS) with iron overload treated with deferasirox.
Mots clés
deferasirox, iron chelation, myelodysplastic syndrome, transfusion
Référence
Eur. J. Haematol.. 2018 May 2;: